Daptomycin

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Retrieved on: 
Thursday, September 28, 2023

ERADICATE is the largest registrational study for SAB conducted to date and ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in the treatment of SAB.

Key Points: 
  • ERADICATE is the largest registrational study for SAB conducted to date and ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in the treatment of SAB.
  • Using a pre-defined non-inferiority margin of 15%, treatment with ceftobiprole was non-inferior to daptomycin with overall treatment success achieved in 69.8% of patients in the ceftobiprole group compared to 68.7% in the daptomycin group.
  • The results for the primary study outcome were consistent in key subgroups, including patients with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA).
  • Ceftobiprole was generally well tolerated and showed a safety profile consistent with previous phase 3 studies and the post-marketing experience.

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023

“We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter.

Key Points: 
  • “We remain on track to file an IND for our second program, CF-370, which is our engineered lysin targeting Gram-negative pathogens, in the third quarter.
  • Research and development (R&D) expenses were $4.9 million for the second quarter of 2023 compared to $16.8 million in the comparable period in 2022.
  • General and administrative (G&A) expenses were $3.1 million for the second quarter of 2023 compared to $3.3 million in the comparable period in 2022.
  • As of June 30, 2023, ContraFect had cash and cash equivalents of $14.4 million.

Andira Pharmaceuticals’ US Patent Allowed in Breakthrough Therapeutic Treatment to Address Deadly Antibiotic-Resistant Infections

Retrieved on: 
Thursday, August 10, 2023

Andira has announced that it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) for US Patent Application No.

Key Points: 
  • Andira has announced that it has received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) for US Patent Application No.
  • 17/589,588 “Antibiotic Cannabinoid-Terpene Formulations.” Andira Pharmaceuticals is the sole exclusive worldwide licensee of the patent.
  • “The allowance of this patent is an important milestone toward successfully addressing hospital-acquired infections that are resistant to antibiotics.” said Dr. Dana Lambert, President and CEO of Andira.
  • “Andira has an extensive global IP portfolio, and this issuance from USPTO is another significant milestone achievement for Andira.

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

Retrieved on: 
Tuesday, June 20, 2023

“The data presented at ASM Microbe is quite powerful.

Key Points: 
  • “The data presented at ASM Microbe is quite powerful.
  • Both dose regimens of CF-370 in addition to amikacin significantly reduced bacteria counts compared to all other treatment groups (p≤0.0001).
  • The results of this study reproduce the efficacy seen in previously released data presented at ECCMID 2023 further demonstrating the bactericidal power of CF-370 against XDR strains of Gram-negative pathogens.
  • The results of this study reinforce previously released data demonstrating the power of both CF-296 and exebacase when delivered locally in the rabbit osteomyelitis model.

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Retrieved on: 
Tuesday, March 14, 2023

Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Key Points: 
  • Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.
  • Oragenics’ lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
  • Oragenics is focused on addressing this unmet medical need through its novel lantibiotics platform, and the results of its work with Linnaeus Bioscience advance Oragenics’ long-term mission to become a provider of effective treatments for infectious diseases.
  • Oragenics remains committed to fighting infectious diseases through the development of its lantibiotics pipeline against MRSA and VRE pathogens.

ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

Retrieved on: 
Monday, December 19, 2022

All patients in the DISRUPT study have now been independently adjudicated and the study database has been locked.

Key Points: 
  • All patients in the DISRUPT study have now been independently adjudicated and the study database has been locked.
  • The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the United States in 259 of the planned 348 patients with S. aureus bacteremia, including right-sided endocarditis.
  • Enrollment in the trial was stopped following a review of the pre-specified, interim futility analysis by the independent Data Safety Monitoring Board (DSMB).
  • The company is planning a virtual fireside chat in the first quarter of 2023 for an in-depth review and discussion of the DISRUPT study.

Accord Healthcare Inc. Issues Nationwide Voluntary Recall of Daptomycin for Injection 500 mg/vial and Daptomycin for Injection 350 mg/vial Lot # R2200232 Due to Product Mix-up

Retrieved on: 
Friday, December 23, 2022

Daptomycin for Injection 350 mg/vial and 500 mg/vial were distributed nationwide to wholesale.

Key Points: 
  • Daptomycin for Injection 350 mg/vial and 500 mg/vial were distributed nationwide to wholesale.
  • Accord is notifying or has notified its Wholesalers and Distributors by letter and is arranging for return of all recalled products.
  • Wholesalers and Distributors that have product which is being recalled should discontinue distribution of the product.
  • Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Acute Bacterial Skin and Skin Structure Infections Global Market Report 2022: Acquisition of Drug Distribution Rights A Key Growth Factor - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022

Market players are acquiring drug distribution rights in various countries, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period.

Key Points: 
  • Market players are acquiring drug distribution rights in various countries, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period.
  • Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of acute bacterial skin and skin structure infections.
  • Increasing research and development by the key players for the development of new drugs to treat global acute bacterial skin and skin structure infections is expected to propel growth of the global acute bacterial skin and skin structure infections market.
  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type:

ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections

Retrieved on: 
Monday, September 12, 2022

The authors conclude that these advantages could compensate for the treatment challenges with current antibiotic treatments against staphylococcal BJIs alone.

Key Points: 
  • The authors conclude that these advantages could compensate for the treatment challenges with current antibiotic treatments against staphylococcal BJIs alone.
  • Exebacase displayed significant anti-biomass and bactericidal activity against S. epidermidis biofilms, as well as synergistic effects in addition to rifampicin, vancomycin, and daptomycin.
  • Prosthetic joint infections are particularly problematic, often requiring joint removal and reimplantation.
  • ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections.

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis

Retrieved on: 
Monday, August 15, 2022

This manuscript presents the results from a study evaluating the activity of exebacase or the CF-296 lysin in a preclinical rabbit model of implant-associated methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.

Key Points: 
  • This manuscript presents the results from a study evaluating the activity of exebacase or the CF-296 lysin in a preclinical rabbit model of implant-associated methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.
  • Notably, the administration of exebacase alone, without systemic antibiotics, resulted in significant reductions in MRSA counts compared to controls.
  • Furthermore, either exebacase or CF-296, used in addition to systemically administered daptomycin, also resulted in significant reduction in MRSA counts on infected implants compared to daptomycin alone.
  • Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made.